The Nordic market is one of the most attractive regions in European MedTech. High healthcare spending, strong clinical infrastructure, and a willingness to adopt innovative technologies make it a natural target for market entry.
But the Nordics are not a single market. They are four distinct countries with different procurement systems, reimbursement models, and competitive dynamics. Companies that treat "the Nordics" as one homogeneous region consistently underperform.
Here are five mistakes we see MedTech companies make when entering the Nordic market.
1. Treating the Nordics as One Market
Sweden, Norway, Denmark, and Finland share cultural similarities, but their healthcare systems are fundamentally different. Sweden uses a decentralized regional procurement model. Denmark has increasingly centralized purchasing through Amgros. Norway operates through regional health authorities with significant autonomy. Finland has a mixed model with hospital districts and municipal procurement.
A go-to-market strategy that works in Sweden may fail completely in Denmark. Successful companies develop country-specific approaches within a Nordic framework.
2. Underestimating the Tender Process
Public procurement dominates Nordic MedTech purchasing. Tenders are structured, formal, and often multi-year. Companies that are accustomed to relationship-driven selling in other European markets find the Nordic tender process challenging.
The key is preparation. Winning tenders requires clinical evidence, health economic data, service commitments, and pricing that aligns with the specific evaluation criteria. This preparation needs to start 12 to 18 months before the tender is published.
3. Choosing the Wrong Channel Strategy
The decision between direct sales, distribution, and hybrid models is critical in the Nordics. Many companies default to appointing a distributor without understanding the strategic implications.
Distributors provide reach but limit control over pricing, customer relationships, and clinical education. Direct presence provides control but requires significant investment. The right choice depends on product complexity, clinical education requirements, and long-term strategic intent.
4. Ignoring Key Opinion Leader Engagement
Nordic clinicians are highly influential in procurement decisions. Their recommendations carry significant weight in tender evaluations and clinical adoption.
Companies that focus exclusively on procurement teams while neglecting clinical engagement miss a critical success factor. KOL development in the Nordics requires a structured, long-term approach built on clinical evidence and peer-to-peer education.
5. Pricing Without Understanding Value-Based Procurement
Nordic healthcare systems are increasingly moving toward value-based procurement. This means that the lowest price does not always win. Buyers evaluate total cost of ownership, clinical outcomes, and service quality alongside unit price.
Companies that compete solely on price in the Nordics leave value on the table. A strong value proposition backed by clinical evidence and health economic data can support premium pricing even in competitive tender situations.
The Path Forward
Successful Nordic market entry requires deep local knowledge, realistic timelines, and a willingness to invest in the foundations before expecting returns. Companies that get this right find the Nordics to be one of the most rewarding regions in European MedTech.